Journal article icon

Journal article

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Abstract:

BACKGROUND: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome. METHODS: In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1056/nejmoa1400376

Authors


Expand authors...
Publisher:
Massachussetts Medical Society
Journal:
The New England journal of medicine
Volume:
371
Issue:
3
Pages:
213-223
Publication date:
2014-07-05
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
URN:
uuid:94ed6162-805c-4b48-8ada-f98fabde922f
Source identifiers:
477988
Local pid:
pubs:477988

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP